Description | This product is a neutralizing antibody that binds to Severe Acute Respiratory Syndrome Coronavirus 2. P2C-1F11 is capable of specifically binding with SARS-CoV-2 and shows a good capacity to neutralize the SARS-CoV-2. |
Clonality | Monoclonal |
Host Species | Human |
Target Species | SARS-CoV-2 |
Epitope | RBD receptor binding domain |
Isotype | IgG1 |
Expression Species | HEK293F or CHO cell line |
Conjugation | Unconjugated |
Purity | >95% |
Endotoxin | <1 EU/mg |
Form | Liquid |
Purification | Protein A purified |
Sterility | 0.2 μM filtered |
Formulation | PBS, pH 7.4 |
Preservation | No preservatives |
Stabilizer | No stabilizers |
Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
Application | ELISA |
Application Notes | ELISA plates were coated overnight at 4°C with 200 ng per well of SARS-CoV-2 RBD or GX/P2V/2017 RBD protein in 0.05 M carbon_x0002_ate-bicarbonate buffer (pH 9.6) and blocked with 5% skimmed milk in PBS. The serum was serially diluted and added to each well. After incubation at 37_x0003_°C for 1 h, the plates were washed three times with 0.05% Tween 20 in PBS and incubated with goat anti-human IgG_x0002_HRP antibody for 1 h. After intensive washing,TMB substrate was added to each well. The reaction was stopped with 2 M hydrochloric acid and the absorbance was measured at 450 nm using a microplate reader. The endpoint titer was defined as the highest reciprocal dilution of serum to give an absorbance greater than 2.1-fold of the background values. The antibody titers below the limit of detection were determined as half of the limit of detection. |
ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
WB | Western Blot Protocol |
FC | Flow Cytometry Protocol |
Target | SARS-CoV-2 |
Alternative Name | Severe acute respiratory syndrome coronavirus 2 |
Research Area | Coronavirus Disease 2019 |
Related Disease | Coronavirus Disease 2019 |